ALZHEIMER’S CONCERNS ?
Are you concerned about developing Alzheimer’s or Mild Cognitive Impairment for yourself or someone in your family?
NEW BLOOD TESTS AVAILABLE:
Did you know there are now blood tests available that can show certain biomarkers for predicting who will develop Alzheimer’s even if there are no noticeable cognitive signs of impairment at the present time?
PARTICIPATE IN THE SOLUTION:
Certain at-risk patients experiencing Mild Cognitive Impairment (MCI) or early-stage Alzheimer’s may be eligible to participate in a new pilot program that uses existing FDA approved medications. These existing medications have been repurposed in a new triple combination (ZN300) in order to slow, stop, or prevent Mild Cognitive Impairment and early-stage Alzheimer’s. Patients in the pilot program will be tested periodically with the new blood testing methods to confirm the patient’s biomarkers have slowed, improved, or reversed from their initial test readings.
LabCorp ATN Profile Test Details
( Quest Diagnostics offers similar testing )
( Please contact Zachriel Neurosciences for more details )
Questionnaire For More Details On the ZN Pilot Treatment Program
We encourage anyone concerned with early-stage Alzheimer’s and or Mild Cognitive Impairment to seek their doctor's advice on taking the blood tests and to contact us for more details about participating in our new pilot treatment program for Mild Cognitive Impairment and early-stage Alzheimer’s. Participants would be utilizing existing FDA medications that have been repurposed in a new proprietary combination that focuses on the three main causes of MCI and early-stage Alzheimer’s according to our research and discoveries by our founder Dr. Michael D’Andrea. For more details, please fill out the online questionnaire and either have your doctor or you contact us for more details about participating in our new pilot treatment program.
PLEASE CONSIDER DONATING TO THE PILOT TREATMENT PROGRAM
EVERY DONATION HELPS
Support the Solution Pilot Program
$2,500 Supports a Patient for 6 Months
$5,000 Supports a Patient for 12 Months
For Patients Without Full Insurance Coverage
While ZN anticipates improvements in the Blood Test Biomarkers to appear within 6, 12, or 18 weeks from an individual’s start date, continued treatment and blood testing may need to continue for months or years to confirm the biomarkers continue to slow, improve, or reverse from their initial readings depending upon the individual's condition.